Latest Articles about ARRY

Array Presents ARRY-520 Data - Analyst Blog

Zacks Equity Research — Thu, 11 Apr 2013 03:09:13 Z

Array BioPharma, Inc. ( ARRY ) recently presented data on ARRY-520 from two ongoing studies in multiple myeloma. In 2012, Array BioPharma made progress on its proprietary programs ARRY-614

Gilead Seeks FDA Approval - Analyst Blog

Zacks Equity Research — Wed, 10 Apr 2013 01:10:25 Z

Gilead Sciences ( GILD ) recently submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval to market its hepatitis C Virus (HCV) candidate

Regeneron Aims HQ Expansion - Analyst Blog

Zacks Equity Research — Tue, 09 Apr 2013 02:06:29 Z

Regeneron Pharmaceuticals ( REGN ) announced recently that it intends to expand its corporate headquarters and laboratories in Westchester County, New York. The move is expected to create

BMY Announces Management Changes - Analyst Blog

Zacks Equity Research — Tue, 09 Apr 2013 01:53:01 Z

Bristol-Myers Squibb Company ( BMY ) recently appointed Francis Cuss as its executive vice president and chief scientific officer. The arrangement is effective from Jul 1, 2013. Cuss

R&D and Iclusig Update from Ariad - Analyst Blog

Zacks Equity Research — Sat, 06 Apr 2013 02:08:24 Z

Ariad Pharmaceuticals, Inc. ( ARIA ) recently provided an update on its pipeline and the commercialization of Iclusig in the US. We remind investors that in Dec 2012, Iclusig gained the US

Orphan Status for Insmed's Arikace - Analyst Blog

Zacks Equity Research — Fri, 05 Apr 2013 00:07:41 Z

The US Food and Drug Administration (FDA) Office of Orphan Products Development recently granted orphan drug designation to Insmed Incorporated 's ( INSM ) candidate, Arikace for the

BioMarin Files CTA for BMN-190 - Analyst Blog

Zacks Equity Research — Wed, 03 Apr 2013 18:22:52 Z

BioMarin Pharmaceutical Inc. ( BMRN ) recently submitted a Clinical Trial Application (CTA) with the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for BMN-190.

BMRN Seeks US Approval of Vimizim - Analyst Blog

Zacks Equity Research — Wed, 03 Apr 2013 00:17:57 Z

BioMarin Pharmaceutical Inc. ( BMRN ) recently submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Vimizim (BMN-110, elosulfase alfa). BioMarin

ANTH's Blisibimod Enters Phase III - Analyst Blog

Zacks Equity Research — Tue, 02 Apr 2013 03:11:38 Z

Anthera Pharmaceuticals Inc. ( ANTH ) recently initiated the CHABLIS-SC1 phase III study on blisibimod. Blisibimod is being developed for treating patients suffering from systemic lupus

Pipeline Progress at Pluristem - Analyst Blog

Zacks Equity Research — Tue, 26 Mar 2013 02:31:03 Z

Israel-based Pluristem Therapeutics Inc. ( PSTI ) recently reported progress on its phase I/II clinical trial, which is evaluating the safety and efficacy of its PLacental eXpanded (PLX)

Pipeline Setback at BioLineRx - Analyst Blog

Zacks Equity Research — Tue, 26 Mar 2013 00:29:40 Z

BioLineRx ( BLRX ) recently announced disappointing results from an interim analysis of the phase II/III CLARITY trial of BL-1020. The company's share price was down by almost 53% on the

Mid-Afternoon Market Update: VrinetX Falls as Veeco Continues to Boost

Jake L'Ecuyer — Mon, 25 Mar 2013 23:37:52 Z

Toward the end of trading Monday, the Dow traded down 0.48 percent to 14,452.18 while the NASDAQ dropped 0.33 percent to 3,234.06. The S&P also fell, dropping 0.38 percent to 1,551.26.

Mid-Day Market Update: Markets Turn Red, Apollo Group Surges On Upbeat Results

Jake L'Ecuyer — Mon, 25 Mar 2013 21:11:57 Z

Midway through trading Monday, the Dow traded down 0.41 percent to 14,453.18 while the NASDAQ dropped 0.37 percent to 3,233.06. The S&P also fell, dropping 0.30 percent to 1,552.26.

Mid-Morning Market Update: Markets Rise On Cyprus Deal, Dollar General Posts Higher Profit

Jake L'Ecuyer — Mon, 25 Mar 2013 19:03:29 Z

Following the market opening Monday, the Dow traded up 0.31 percent to 14,556.33 while the NASDAQ gained 0.41 percent to 3,258.20. The S&P also rose, gaining 0.47 percent to 1,564.17.

Data on BioMarin's BMN-701 - Analyst Blog

Zacks Equity Research — Fri, 22 Mar 2013 02:26:38 Z

BioMarin Pharmaceutical Inc. ( BMRN ) recently announced positive results on BMN-701 from the phase I/II study, POM-001. BMN-701 is a fusion protein of insulin-like growth factor 2 and acid